Sight Sciences, Inc. (SGHT)

Over the past six months, Sight Sciences' stock has experienced several notable events. The stock price has trended up by 6.98%. In Q4 2025, the company reported total revenue of $20.4 million, a 7% increase, and a net loss of $4.2 million, or $0.08 per share. The U.S. District Court issued an order preserving a jury's verdict that Alcon Inc. willfully infringed three of Sight Sciences' patents, awarding Sight Sciences $34 million in monetary damages and an ongoing royalty of 10% of Hydrus Microstent revenue. In Q3 2025, total revenue was $19.9 million, a 1% decrease, with Surgical Glaucoma revenue increasing by 6% and Dry Eye segment revenue decreasing by 88%. The company reduced its workforce by approximately 20% to cut costs. Sight Sciences has been the subject of 6 research reports, with a consensus rating of "Hold" and an average rating score of 2.44. The consensus price target is $8.31, representing about 114.2% upside.

Sight Sciences exhibits seasonal tendencies in its stock performance based on historical data over five years. November has been the strongest month, with an average return of 34.78%, while September tends to be the weakest month, averaging a -17.98% return. The overall monthly win rate for the stock is 41.7%, with six months typically showing positive average returns. The seasonal pattern has a consistency score of 43.2 (Poor), indicating that while patterns exist, their reliability can vary.

Sight Sciences, Inc. is an ophthalmic medical device company focused on developing and commercializing surgical and non-surgical technologies for eye diseases. The company operates in the Healthcare sector, specifically the Medical Devices & Instruments industry, with a mission to transform eye care by targeting the underlying causes of these diseases using minimally invasive or non-invasive approaches. The company's major products are categorized into Interventional Glaucoma, which includes the OMNI Surgical System and the SION Surgical Instrument, and Interventional Dry Eye, which features the TearCare System. The OMNI Surgical System is used to reduce intraocular pressure in adult patients with primary open-angle glaucoma. The SION Surgical Instrument is a bladeless, manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork. The TearCare System applies localized heat therapy to adult patients with evaporative dry eye disease due to meibomian gland dysfunction.

Sight Sciences, Inc. is headquartered in Menlo Park, California, and has expanded its direct sales operations to include the United Kingdom and Germany prior to 2025.

Sight Sciences' brand reputation has been positively impacted by a legal victory in March 2026. The U.S. District Court's order, preserving a jury's verdict that Alcon willfully infringed on Sight Sciences' patents and awarding substantial damages and ongoing royalties, reinforces the strength of Sight Sciences' intellectual property in interventional glaucoma, enhancing the company's credibility and standing.

Sight Sciences is owned by a mix of institutional shareholders, insiders, and retail investors. Approximately 36.19% to 55.51% of the stock is held by institutions, including KCK LTD., Long Focus Capital Management LLC, and Invesco Ltd. Insiders hold a significant proportion, ranging from 30.90% to 57.63% of the company's stock, with key individual shareholders including Staffan Encrantz and Paul Badawi. The general public, including retail investors, owns about 6.18% to 30% of the company's shares.